Pucéat M, Vassort G
Laboratoire de Physiopathologie Cardiovasculaire, INSERM U390, Montpellier, France.
Mol Cell Biochem. 1996;157(1-2):65-72. doi: 10.1007/BF00227882.
Understanding transmembrane signalling process is one of the major challenge of the decade. In most tissues, since Fisher and Krebs's discovery in the 1950's, protein phosphorylation has been widely recognized as a key event of this cellular function. Indeed, binding of hormones or neurotransmitters to specific membrane receptors leads to the generation of cytosoluble second messengers which in turn activate a specific protein kinase. Numerous protein kinases have been so far identified and roughly classified into two groups, namely serine/threonine and tyrosine kinases on the basis of the target acid although some more recently discovered kinases like MEK (or MAP kinase kinase) phosphorylate both serine and tyrosine residues. Protein kinase C is a serine/threonine kinase that was first described by Takai et al. [1] as a Ca- and phospholipid-dependent protein kinase. Later on, Kuo et al. [2] found that PKC was expressed in most tissues including the heart. The field of investigation became more complicated when it was found that the kinase is not a single molecular entity and that several isoforms exist. At present, 12 PKC isoforms and other PKC-related kinases [3] were identified in mammalian tissues. These are classified into three groups. (1) the Ca-activated alpha-, beta-, and gamma-PKCs which display a Ca-binding site (C2); (2) the Ca-insensitive delta-, epsilon-, theta-, eta-, and mu-PKCs. The kinases that belong to both of these groups display two cysteine-rich domains (C1) which bind phorbol esters (for recent review on PKC structure, see [4]). (3) The third group was named atypical PKCs and include zeta, lambda, and tau-PKCs that lack both the C2 and one cysteine-rich domain. Consequently, these isoforms are Ca-insensitive and cannot be activated by phorbol esters [5]. In the heart, evidence that multiple PKC isoforms exist was first provided by Kosaka et at. [6] who identified by chromatography at least two PKC-related isoenzymes. Numerous studies were thus devoted to the biochemical characterization of these isoenzymes (see [7] for review on cardiac PKCs) as well as to the identification of their substrates. This overview aims at updating the present knowledge on the expression, activation and functions of PKC isoforms in cardiac cells.
理解跨膜信号传导过程是这十年的主要挑战之一。自20世纪50年代费希尔和克雷布斯发现以来,在大多数组织中,蛋白质磷酸化已被广泛认为是这种细胞功能的关键事件。事实上,激素或神经递质与特定膜受体的结合会导致产生可溶于细胞质的第二信使,进而激活特定的蛋白激酶。到目前为止,已经鉴定出许多蛋白激酶,并根据靶酸大致分为两组,即丝氨酸/苏氨酸激酶和酪氨酸激酶,尽管一些最近发现的激酶如MEK(或丝裂原活化蛋白激酶激酶)会使丝氨酸和酪氨酸残基都发生磷酸化。蛋白激酶C是一种丝氨酸/苏氨酸激酶,最初由高井等人[1]描述为一种依赖钙和磷脂的蛋白激酶。后来,郭等人[2]发现蛋白激酶C在包括心脏在内的大多数组织中都有表达。当发现该激酶不是单一的分子实体且存在几种同工型时,研究领域变得更加复杂。目前,在哺乳动物组织中鉴定出了12种蛋白激酶C同工型和其他与蛋白激酶C相关的激酶[3]。它们被分为三组。(1)钙激活的α-、β-和γ-蛋白激酶C,它们具有一个钙结合位点(C2);(2)对钙不敏感的δ-、ε-、θ-、η-和μ-蛋白激酶C。属于这两组的激酶都有两个富含半胱氨酸的结构域(C1),它们能结合佛波酯(有关蛋白激酶C结构的最新综述,请参见[4])。(3)第三组被称为非典型蛋白激酶C,包括ζ、λ和τ-蛋白激酶C,它们既没有C2结构域,也没有一个富含半胱氨酸的结构域。因此,这些同工型对钙不敏感且不能被佛波酯激活[5]。在心脏中,小坂等人[6]首先提供了存在多种蛋白激酶C同工型的证据,他们通过色谱法鉴定出至少两种与蛋白激酶C相关的同工酶。因此,许多研究致力于这些同工酶的生化特性研究(有关心脏蛋白激酶C的综述,请参见[7])以及它们底物的鉴定。本综述旨在更新目前关于蛋白激酶C同工型在心肌细胞中的表达、激活和功能的知识。